KR20090085445A - MANUFACTURING PROCESS OF 2-AMINOMALONAMIDE AS INTERMEDIATE FOR PRODUCING 4-CARBAMOYL-1-beta;-D-RIBOFURANOSYLIMIDAZOLIUM-5-OLATE - Google Patents
MANUFACTURING PROCESS OF 2-AMINOMALONAMIDE AS INTERMEDIATE FOR PRODUCING 4-CARBAMOYL-1-beta;-D-RIBOFURANOSYLIMIDAZOLIUM-5-OLATE Download PDFInfo
- Publication number
- KR20090085445A KR20090085445A KR1020080011344A KR20080011344A KR20090085445A KR 20090085445 A KR20090085445 A KR 20090085445A KR 1020080011344 A KR1020080011344 A KR 1020080011344A KR 20080011344 A KR20080011344 A KR 20080011344A KR 20090085445 A KR20090085445 A KR 20090085445A
- Authority
- KR
- South Korea
- Prior art keywords
- carbamoyl
- aminomalonamide
- olate
- oleate
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
본 발명은 하기 화학식 1로 표시된 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트의 생산을 위한 중간체로서의 2-아미노말론아미드의 제조방법에 관한 것으로, 거의 발효에 의해 생산되고 있는 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트의 생산 공정을 개선하여 화학반응에 의한 방법으로 생산 가능하도록 출발물질을 달리한 신규한 합성 방법에 관한 것이다.The present invention relates to a method for preparing 2-aminomalonamide as an intermediate for the production of 4-carbamoyl-1-β-D-ribofuranoslimidazolium-5-oleate represented by the following formula (1) New starting materials with different starting materials to be produced by chemical reaction by improving the production process of 4-carbamoyl-1-β-D-ribofuranoslimidazolium-5-oleate produced by fermentation One method of synthesis relates.
4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트(4-carbamoyl-1-β-D-ribofuranosylimidazolium-5-olate)는 면역억제제로 사용되었고, 루프스 신염, 만성통증 관절 류마티즘 등의 치료약으로 우수한 약물로 알려져 있다. 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트의 제조법으로서는 여러 방법이 알려져 있으며 대표적 합성법은 반응식 1로 표시된 아래와 같다 [참조 : J. Antibiotics, 27, (10), 775(1974); Chem. Pharm. Bull., 23, 245(1975)].4-carbamoyl-1-β-D-ribofuranosylimidazolium-5-olate was used as an immunosuppressive agent, lupus nephritis, It is known as an excellent drug for the treatment of chronic pain joint rheumatism. There are several known methods for preparing 4-carbamoyl-1-β-D-ribofuranosilimidazolium-5-oleate, and the representative synthesis method is shown in Scheme 1 below. [J. Antibiotics, 27, ( 10), 775 (1974); Chem. Pharm. Bull., 23, 245 (1975).
반응식 1로 표시된 총 6 단계인 기존의 합성 방법은 화학합성적으로 생산하기에 여러가지 제약이 따르고 있다.The conventional synthesis method, which is a total of six steps represented by Scheme 1, is subject to various limitations in the production of chemical synthesis.
첫째 핵심중간체인 2-아미노말론아미드 (화학식 2, 반응식 1에서 3으로 표시)를 얻기 위해 인화성이 강한 팔라듐 차콜 (통상적으로 Pd/C로 표시)을 사용하여 고압하에서 수소화 반응을 진행시켜야 하고, 둘째 4-카르바모일-1-(2,3,5-트리-O-아세틸-β-D-리보퓨라노실)이미다졸륨-5-올레이트 (반응식 1에서 5로 표시)를 얻기 위해 -60 ℃에서부터 60 ℃까지 18 시간 이상 반응하며, 반응 종료 후 순수한 화합 물을 얻기 위해 클로로포름과 메탄올을 전개용매로 이용한 컬럼크로마토그래피를 이용해야 할 뿐만 아니라, 셋째 최종 목적화합물인 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트를 얻기 위하여 클로로포름과 메탄올, 무수초산을 전개 용매로 하여 컬럼크로마토그래피를 통한 분리 단계를 거쳐 불순물을 제거해야 한다. 이러한 생산공정상의 비효율성으로 인하여 기존의 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트의 제공은 화학적 합성법에 비해 현저하게 효율이 떨어지는 미생물에 의한 발효에 의존한 방법이 대부분이었다.First, hydrogenation reaction should be carried out under high pressure using highly flammable palladium charcoal (typically denoted as Pd / C) to obtain 2-aminomalonamide (formula 2, represented by Scheme 1 in 3), the key intermediate. To obtain 4-carbamoyl-1- (2,3,5-tri-O-acetyl-β-D-ribofuranosyl) imidazolium-5-oleate (denoted 5 in Scheme 1)- It reacts for more than 18 hours from 60 ℃ to 60 ℃, and after completion of the reaction to obtain a pure compound not only has to use column chromatography using chloroform and methanol as a developing solvent, the third final compound 4-carbamoyl- In order to obtain 1-β-D-ribofuranosilimidazolium-5-oleate, impurities must be removed by column chromatography using chloroform, methanol, and acetic anhydride as a developing solvent. Due to such inefficiency in the production process, the provision of conventional 4-carbamoyl-1-β-D-ribofuranosilimidazolium-5-oleate has been found to be effective for fermentation by microorganisms which are significantly less efficient than chemical synthesis. Most of them depended.
본 발명은 상기와 같은 문제점을 해결하기 위하여 안출된 것으로서, 출발물질의 변경 및 반응 공정의 개선을 통해 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트를 효과적으로 합성하는 방법을 제공하는 것을 목적으로 한다. The present invention has been made to solve the above problems, 4-carbamoyl-1-β-D-ribofuranosilimidazolium-5-oleate through the modification of the starting material and the improvement of the reaction process It is an object to provide a method for synthesizing effectively.
또한 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트를 합성하기 위해 필요한 화학식 2로 표시된 중간체 합성방법을 제공하는 것을 또 다른 목적으로 한다.It is another object of the present invention to provide a method for synthesizing the intermediate represented by the formula (2) necessary for synthesizing 4-carbamoyl-1-β-D-ribofuranosilimidazolium-5-oleate.
본 발명의 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트 제조방법은 상술한 바와 같은 목적을 달성하기 위하여,4-carbamoyl-1-β-D-ribofuranosilimidazolium-5-oleate production method of the present invention, in order to achieve the object as described above,
(A) 디에틸 2-아미노말로네이트 (diethyl 2-aminomalonate)를 암모니아와 반응시켜 2-아미노말론아미드 (2-aminomalonamide)를 합성하는 단계; (A) reacting diethyl 2-aminomalonate with ammonia to synthesize 2-aminomalonamide;
(B) 상기 2-아미노말론아미드를 포름아미딘 아세테이트 (formamidine acetate)와 반응시켜 2-이미다졸륨-5-올레이트 (2-imidazolium-5-olate)를 합성하는 단계; (B) reacting the 2-aminomalonamide with formamidine acetate to synthesize 2-imidazolium-5-olate;
(C) 상기 2-이미다졸륨-5-올레이트를 루이스 산의 존재 하에서 퓨라노즈 테트라에스테르 (furanose tetraester)와 커플링반응시키는 단계; 및 (C) coupling the 2-imidazolium-5-oleate with furanose tetraester in the presence of Lewis acid; And
(D) 상기 커플링반응 생성물의 보호기를 이탈시켜 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트를 수득하는 단계(D) leaving the protecting group of the coupling reaction product to obtain 4-carbamoyl-1-β-D-ribofuranosilimidazolium-5-oleate
를 포함하는 것을 특징으로 한다.Characterized in that it comprises a.
또한, 본 발명의 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트 제조방법은 상기 단계 (A)의 반응이 메탄올 중에서 이루어지는 것이 바람직하다.In addition, in the method for preparing 4-carbamoyl-1-β-D-ribofuranoslimidazolium-5-oleate of the present invention, the reaction of step (A) is preferably performed in methanol.
한편, 본 발명의 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트 생산을 위한 중간체로서의 화학식 2의 2-아미노말론아미드 (2-aminomalonamide)의 제조방법은 디에틸 2-아미노말로네이트 (diethyl 2-aminomalonate)를 암모니아와 반응시키는 것을 특징으로 한다.On the other hand, the preparation method of 2-aminomalonamide of the formula (2) as an intermediate for the production of 4-carbamoyl-1-β-D-ribofuranoslimidazolium-5-oleate of the present invention It is characterized by reacting diethyl 2-aminomalonate with ammonia.
또한, 상기 디에틸 2-아미노말로네이트와 암모니아와의 반응은 메탄올 중에서 이루어지는 것이 바람직하다.Moreover, it is preferable that reaction of the said diethyl 2-aminomalonate and ammonia is made in methanol.
본 발명은 종래 6 단계로 진행되던 공정을 네 단계로 줄여 공정을 크게 단축시켰으며, 가압 수소화 반응 공정이나 루이스 산 존재하에서의 가혹한 반응조건을 사용하지 않고 훨씬 온화한(mild) 조건에서 중간체를 얻을 수 있어 생산의 안전성을 증대시켰고, 이를 통해 전체 생산효율을 크게 향상시킬 수 있는 장점이 있다.The present invention significantly reduces the process by reducing the process that was performed in the conventional six steps to four steps, and can obtain intermediates at much milder conditions without using a pressurized hydrogenation process or harsh reaction conditions in the presence of Lewis acid. Increased safety of production, through which there is an advantage that can greatly improve the overall production efficiency.
총 6 단계인 상기 반응식 1로 표시된 기존의 합성 방법에 비해 하기 반응식 2로 표시된 본 발명의 합성법은 총 4 단계로 이루어진다. 반응식 1에서 핵심중간체인 2-아미노말론아미드 (화학식 2. 반응식 1 및 2에서 3으로 표시)를 얻기 위해 3 단계에 걸친 반응과 고압의 수소화 반응을 이용하던 것을 디에틸 2-아미노말로네이트 (반응식 2에서 6으로 표시)를 이용한 1 단계만으로 합성함으로써, 공정단계를 크게 줄이고 공정의 안전성을 확보하여 대량 합성이 가능케 하였다.Compared to the conventional synthesis method represented by Scheme 1, which is a total of six steps, the synthesis method of the present invention represented by Scheme 2 includes four steps. In order to obtain 2-aminomalonamide, which is a key intermediate in Scheme 1, represented by Schemes 1 and 2 and 3, diethyl 2-aminomalonate was used. By synthesizing in only one step using 2 to 6), large-scale synthesis was possible by greatly reducing the process step and securing the safety of the process.
구체적으로, 본 발명의 4-카르바모일-1-β-D-리보푸라노실이미다졸륨-5-올레이트 제조방법은 종래 제조방법에서 말로닉 에스테르로부터 디에틸 2-(히드록시이미노)말로네이트 (diethyl 2-(hydroxyimino)malonate)를 얻는 단계 (1 단계); 디에틸2-(히드록시이미노)말로네이트로부터 2-(히드록시이미노)말론아미드 (2-(hydroxyimino)malonamide)를 얻는 단계 (2 단계); 2-(히드록시이미노)말론아미드로부터 가압 수소화 반응을 이용하여 2-아미노말론아미드(2-aminomalonamide)를 합성하는 단계 (3 단계)인 세 단계를, 디에틸 2-아미노말로네이트 (diethyl 2-aminomalonate)를 이용하여 수소화 반응을 사용하지 않고 하나의 단계로 단순화함 으로써 공정의 안전성을 확보하며 공정의 단축이 가능하다.Specifically, the method for preparing 4-carbamoyl-1-β-D-ribofuranoslimidazolium-5-oleate of the present invention is a diethyl 2- (hydroxyimino) malonate from a malonic ester in a conventional manufacturing method. Obtaining dinate 2- (hydroxyimino) malonate (step 1); Obtaining 2- (hydroxyimino) malonamide from diethyl2- (hydroxyimino) malonate (step 2); Diethyl 2-aminomalonate (diethyl 2-aminomalonamide) is a three-step step of synthesizing 2-aminomalonamide from 3- (hydroxyimino) malonamide using a pressurized hydrogenation reaction. By using aminomalonate), it is possible to shorten the process by securing the safety of the process by simplifying it in one step without using hydrogenation reaction.
이하, 본 발명의 바람직한 실시예에 대하여 상세히 설명한다. 또한, 하기의 설명에서는 구체적인 구성요소 등과 같은 많은 특정사항들이 설명되어 있는데, 이는 본 발명의 보다 전반적인 이해를 돕기 위해서 제공된 것일 뿐 이러한 특정 사항들 없이도 본 발명이 실시될 수 있음은 이 기술분야에서 통상의 지식을 가진 자에게는 자명하다 할 것이다. 그리고, 본 발명을 설명함에 있어서, 관련된 공지 기능 혹은 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.Hereinafter, preferred embodiments of the present invention will be described in detail. In addition, many specific details such as specific components are described in the following description, which is provided to help a more general understanding of the present invention, and the present invention may be practiced without these specific details. It is self-evident to those who have knowledge of the world. In describing the present invention, when it is determined that a detailed description of a related known function or configuration may unnecessarily obscure the subject matter of the present invention, the detailed description thereof will be omitted.
실시예Example
실시예Example : 2-: 2- 아미노말론아미드(2-aminomalonamide)의Of 2-aminomalonamide 합성 synthesis
실온에서 디에틸 2-아미노말로네이트 15 g 을 메탄올 30 ㎖에 녹인 후 암모니아수 200 ㎖를 적가하고 45 ℃로 온도를 올려 8 시간 교반했다. 반응액를 5 ℃로 냉각하여 1 시간 교반 후 생성된 고체를 여과하여 미색 고체의 목적화합물을 수율 65 %로 얻었다.15 g of diethyl 2-aminomalonate was dissolved in 30 ml of methanol at room temperature, 200 ml of ammonia water was added dropwise, and the temperature was raised to 45 ° C and stirred for 8 hours. The reaction solution was cooled to 5 ° C., stirred for 1 hour, and the resulting solid was filtered to yield the target compound as an off-white solid in 65% yield.
1H NMR (DMSO-d6) : δ ppm 7.41 (bs, 1 H), 7.25 (bs, 1 H), 3.79 (s, 1 H), 2.15 (bs, 2 H). 1 H NMR (DMSO-d 6 ): δ ppm 7.41 (bs, 1 H), 7.25 (bs, 1 H), 3.79 (s, 1 H), 2.15 (bs, 2 H).
암모니아수 대신 암모니아 가스를 메탄올에 포화시킨 용액과 반응시켰을 때도 비슷한 수율로 목적화합물을 얻을 수 있었다.When the ammonia gas was reacted with a solution saturated with methanol instead of ammonia water, the target compound was obtained in a similar yield.
반응예Example of reaction 1: 2- 1: 2- 이미다졸륨Imidazolium -5--5- 올레이트의Oleate 합성 synthesis
실온에서 상기 실시예 1에서 합성된 10.5 g의 2-아미노말론아미드에 11.3 g의 포름아미딘 아세테이트 (formamidine acetate)를 넣고 에탄올 300 ㎖를 가하고 3 시간 동안 환류했다. 혼합물을 상온으로 냉각 후 상온에서 12 시간 동안 교반했다. 생성된 고체를 여과하여 얻고, 얻어진 고체를 물 200 ㎖로 재결정하여 청회색 고체의 목적화합물을 수율 60 %로 얻었다 (녹는점: 255 ℃).11.3 g of formamidine acetate was added to 10.5 g of 2-aminomalonamide synthesized in Example 1 at room temperature, and 300 ml of ethanol was added thereto, and the mixture was refluxed for 3 hours. The mixture was cooled to room temperature and then stirred at room temperature for 12 hours. The resulting solid was obtained by filtration, and the obtained solid was recrystallized from 200 ml of water to give a target compound of a blue-gray solid in a yield of 60% (melting point: 255 ° C.).
1H NMR (DMSO-d6) : δ ppm 7,86 (s, 1 H), 7.05 (bs, 1 H), 6.69 (s, 1 H). 1 H NMR (DMSO-d 6 ): δ ppm 7,86 (s, 1 H), 7.05 (bs, 1 H), 6.69 (s, 1 H).
반응예Example of reaction 2: 4- 2: 4- 카르바모일Carbamoyl -1-(2,3,5-트리-O-아세틸-β-D--1- (2,3,5-Tri-O-acetyl-β-D- 리보퓨라노실Ribofuranosil )) 이미다졸륨Imidazolium -5-올레이트의 합성Synthesis of -5-Olate
상기 반응예 1에서 합성된 2-이미다졸륨-5-올레이트 12 g 및 헥사메틸디실라잔 (hexamethyldisilazane. HMDS) 70 g을 m-자일렌 200 ㎖에 첨가하고, 암모늄 설페이트 250 mg을 추가로 첨가한 다음 12 시간 동안 환류 교반했다. 상기 혼합물을 농축한 후 ß-D-리보퓨라노즈 1,2,3,5-테트라아세테이트 (ß-D-ribofuranose 1,2,3,5-tetraacetate) 16 g을 1,2-디클로로에탄 100 ㎖에 녹여 상기 농축 혼합물에 첨가하고, 사염화주석(SnCl4) 7.2 ㎖를 추가로 첨가한 후 상온에서 6 시간 동안 교반했다. 반응 종료 후 감압 증류하여 용매를 제거하고 수득된 오일상의 화합물에 에틸 아세테이트 400 ㎖를 가한 후, 탄산나트륨(Na2CO3) 5 중량% 수용액 300 ㎖를 넣고 10 분간 세차게 교반한 후 유기층을 추출하였다. 수득된 유기층을 다시 탄산나트륨(Na2CO3) 5 중량% 수용액 300 ㎖로 세척한 후 농축하였다. 수득된 오일상의 화합물을 디클로로메탄과 n-헥산으로 재결정하여 연회색 고체의 목적화합물을 수율 70 %로 수득하였다.12 g of 2-imidazolium-5-oleate and 70 g of hexamethyldisilazane (HMDS) synthesized in Reaction Example 1 were added to 200 ml of m-xylene, and 250 mg of ammonium sulfate was further added. After the addition, the mixture was stirred at reflux for 12 hours. After concentrating the mixture, 16 g of ß-D-ribofuranose 1,2,3,5-tetraacetate (ß-D-ribofuranose 1,2,3,5-tetraacetate) was added to 100 ml of 1,2-dichloroethane. It was dissolved in and added to the concentrated mixture, and 7.2 ml of tin tetrachloride (SnCl 4 ) was further added, followed by stirring at room temperature for 6 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure, 400 ml of ethyl acetate was added to the obtained oily compound, 300 ml of a 5% by weight aqueous solution of sodium carbonate (Na 2 CO 3 ) was added thereto, the mixture was stirred vigorously for 10 minutes, and the organic layer was extracted. The obtained organic layer was washed again with 300 ml of a 5 wt% aqueous solution of sodium carbonate (Na 2 CO 3 ) and concentrated. The oily compound thus obtained was recrystallized from dichloromethane and n-hexane to give the title compound as a light gray solid in 70% yield.
m.p. > 201 ℃m.p. > 201 ℃
[α] = -26.3 °[α] = -26.3 °
1H NMR (CDCl3) : δ ppm 8.01 (s, 1 H), 6.04-6.16 (s, 3 H), 5.38 (bs, 1 H), 4.66-4.81 (m, 3 H), 1.98-2.02 (m, 9 H). 1 H NMR (CDCl 3 ): δ ppm 8.01 (s, 1 H), 6.04-6.16 (s, 3 H), 5.38 (bs, 1 H), 4.66-4.81 (m, 3 H), 1.98-2.02 ( m, 9 H).
반응예Example of reaction 3: 4- 3: 4- 카르바모일Carbamoyl -1-β-D--1-β-D- 리보푸라노실이미다졸륨Ribofuranosyl imidazolium -5--5- 올레이트의Oleate 합성 synthesis
상기 반응예 2에서 얻어진 4-카르바모일-1-(2,3,5-트리-O-아세틸-β-D-리보퓨라노실)이미다졸륨-5-올레이트 10 g을 메탄올 100 ㎖에 녹인 후 수산화나트륨 4.2 g을 가하고 상온에서 6 시간 동안 교반했다. 혼합액을 감압 증류하고 디클로로메탄 100 ㎖ 및 물 100 ㎖를 가하고 진한 염산으로 pH를 5.0으로 맞추었다. 유기층을 제거하고 다시 디클로로메탄 50 ㎖로 물층을 씻었다. 수득된 물층을 감압 증류하여 본래 부피의 1/5로 농축하였다. 상온으로 냉각 후 톨루엔 100 ㎖를 가하고 1 시간 동안 환류한 다음 냉각하여 수득되는 고체를, 메탄올로 다시 재결정하여 흰색 고체의 목적화합물을 수율 40 %로 수득하였다.100 ml of methanol of 10 g of 4-carbamoyl-1- (2,3,5-tri-O-acetyl-β-D-ribofuranosyl) imidazolium-5-oleate obtained in Reaction Example 2 was used. After dissolving in, 4.2 g of sodium hydroxide was added thereto and stirred at room temperature for 6 hours. The mixture was distilled under reduced pressure, 100 ml of dichloromethane and 100 ml of water were added, and the pH was adjusted to 5.0 with concentrated hydrochloric acid. The organic layer was removed and the aqueous layer was washed again with 50 ml of dichloromethane. The water layer obtained was distilled under reduced pressure and concentrated to 1/5 the original volume. After cooling to room temperature, 100 ml of toluene was added, refluxed for 1 hour, and the solid obtained by cooling was recrystallized again with methanol to obtain a target compound as a white solid in a yield of 40%.
m.p. > 200 ℃m.p. > 200 ℃
[α] = -27.5 °[α] = -27.5 °
1H NMR (D2O) : δ ppm 8.03 (s, 1 H), 5.58 (s, 1 H), 4.38 (s, 1 H), 4.15 (s, 1 H), 4.15 (s, 1 H), 3.67 (dd, 2 H, J = 1.6, 3.6 Hz). 1 H NMR (D 2 O): δ ppm 8.03 (s, 1 H), 5.58 (s, 1 H), 4.38 (s, 1 H), 4.15 (s, 1 H), 4.15 (s, 1 H) , 3.67 (dd, 2H, J = 1.6, 3.6 Hz).
이상에서는 본 발명의 바람직한 실시예에 대해서 도시하고 설명하였으나, 본 발명은 상술한 특정의 실시예에 한정되지 아니하며, 당해 기술분야에서 통상의 지식을 가진 자라면 본원 발명의 요지를 벗어남이 없이 다양한 변형 실시가 가능함은 물론이다. 따라서, 본 발명의 범위는 위의 실시예에 국한해서 해석되어서는 안되며, 후술하는 특허청구범위 뿐만 아니라 이 특허청구범위와 균등한 것들에 의해 정해져야 할 것이다.Although the above has been illustrated and described with respect to the preferred embodiments of the present invention, the present invention is not limited to the specific embodiments described above, those skilled in the art without departing from the gist of the present invention various modifications Of course, implementation is possible. Therefore, the scope of the present invention should not be construed as being limited to the above embodiments, but should be defined by the claims below and equivalents thereof.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080011344A KR100982720B1 (en) | 2008-02-04 | 2008-02-04 | Manufacturing Process of 2-Aminomalonamide as Intermediate for Producing 4-Carbamoyl-1-?-D-ribofuranosylimidazolium-5-olate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080011344A KR100982720B1 (en) | 2008-02-04 | 2008-02-04 | Manufacturing Process of 2-Aminomalonamide as Intermediate for Producing 4-Carbamoyl-1-?-D-ribofuranosylimidazolium-5-olate |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090085445A true KR20090085445A (en) | 2009-08-07 |
KR100982720B1 KR100982720B1 (en) | 2010-09-17 |
Family
ID=41205466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080011344A KR100982720B1 (en) | 2008-02-04 | 2008-02-04 | Manufacturing Process of 2-Aminomalonamide as Intermediate for Producing 4-Carbamoyl-1-?-D-ribofuranosylimidazolium-5-olate |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100982720B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103827093A (en) * | 2011-09-28 | 2014-05-28 | 富士胶片株式会社 | Crystal of 5-hydroxy-1H-imidazole-4-carboxamide hydrate, crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, and method for producing same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4503235A (en) * | 1983-03-11 | 1985-03-05 | Warner-Lambert Company | Process for producing 4-carbamoyl-1H-imidazolium-5-olate |
-
2008
- 2008-02-04 KR KR1020080011344A patent/KR100982720B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103827093A (en) * | 2011-09-28 | 2014-05-28 | 富士胶片株式会社 | Crystal of 5-hydroxy-1H-imidazole-4-carboxamide hydrate, crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, and method for producing same |
Also Published As
Publication number | Publication date |
---|---|
KR100982720B1 (en) | 2010-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180012788A (en) | Manufacturing method of Bribaracetam | |
WO2017096996A1 (en) | Preparation method for cobimetinib | |
US11384116B2 (en) | Methods of making cholic acid derivatives and starting materials therefor | |
CN101462974B (en) | Process for synthesizing 5-aminovaleric acid hydrochloride | |
KR20110039320A (en) | Stereoselective synthesis of valiolamine | |
EA018376B1 (en) | New chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | |
KR20080027368A (en) | Method for producing nebivolol | |
KR100982720B1 (en) | Manufacturing Process of 2-Aminomalonamide as Intermediate for Producing 4-Carbamoyl-1-?-D-ribofuranosylimidazolium-5-olate | |
KR100980379B1 (en) | Process for the preparation of optically active 5-hydroxy-3-oxoheptanoate derivatives | |
KR20100118747A (en) | Improved preparation method of sarpogrelate hydrochloride | |
KR100714197B1 (en) | Process for the preparation of voglibose | |
EP1907371A1 (en) | Process for preparing 2-methoxycarbonylmethyl-6,6-dimethyl-2- tetrahydropyran carboxylic acid | |
WO2021020998A1 (en) | Method for producing roxadustat | |
JP2020070296A (en) | Method for producing linagliptin | |
KR101386530B1 (en) | Preparation method for 3-amino-9,13b-dihydro-1H-dibenz-[c,f]imidazo[1,5-a]-azepine hydrochloride having improved purity and yield | |
EP3026047A1 (en) | Method for producing heterocyclic compound | |
US20090281301A1 (en) | Manufacturing Process of 2' ,2' - Difluoronucleoside and Intermediate | |
KR20170123132A (en) | Process for Preparing Treprostinil | |
KR20010092864A (en) | Optically active cyanobutantriol derivatives and process for preparing same | |
KR100856133B1 (en) | Improved process for preparing atorvastatin | |
KR100850558B1 (en) | Process for preparing useful in synthesis of atorvastatin | |
CA2460571A1 (en) | Intermediate compounds for the preparation of mirtazapine and obtention methods thereof | |
JP3144920B2 (en) | α-Acylaminoketone derivatives, production method thereof and use thereof | |
KR20160109041A (en) | Process for Production of Optically Active Indoline Derivatives or Salts Thereof | |
SU833941A1 (en) | Method of producing tetracene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130910 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140901 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160909 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170908 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180910 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190910 Year of fee payment: 10 |